Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Pneumonia Therapeutics Market Growth in 2025?
The market size for pneumonia therapeutics has seen a swift expansion in past few years. Projected to climb from $10.35 billion in 2024 to reach $11.49 billion in 2025, it anticipates a compound annual growth rate (CAGR) of 11.0%. The substantial growth observed in the historic period can be credited to factors such as the surge in drug-resistant strains, enhanced consciousness regarding pneumonia prevention, rise in the number of elderly and immunocompromised individuals, implementation of broader vaccination initiatives, and the enhancement of healthcare infrastructure.
What Is the Forecast for the Pneumonia Therapeutics Market Size Through 2029?
It’s anticipated that in the coming years, the market for pneumonia therapeutics will witness considerable expansion. By 2029, it is projected to increase by 10.7% Compound Annual Growth Rate (CAGR), reaching a size of $17.26 billion. The expansion anticipated during the forecast period can be linked to factors such as the rise of antibiotic-resistant strains, the increasing prevalence of pneumonia in the elderly, the proliferation of telemedicine for prompt diagnosis, elevated health care spending in emerging markets, increased funding for infectious disease research, and intensified awareness initiatives. Key trends expected during this forecast period include the creation of monoclonal antibodies, the use of inhalable antibiotics, breakthroughs in mRNA-based vaccines, AI-powered diagnostic instruments, the application of host-targeted therapies, innovative immunomodulators, and improvements in rapid point-of-care diagnostic platforms.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21258&type=smp
What are the Key Market Players in Pneumonia Therapeutics Market and How They’re Evolving?
Major companies operating in the pneumonia therapeutics market are Pfizer Inc., Roche AG, Merck & Co. Inc., AbbVie Inc, Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Shionogi & Co. Ltd, Lupin Limited, Swedish Orphan Biovitrum AB, Nabriva Therapeutics plc, TaiGen Biotechnology Co. Ltd, Aridis Pharmaceuticals Inc., Tergene Biotech Limited.
What Are the Primary Growth Drivers in the Pneumonia Therapeutics Market?
The escalation in pneumonia cases is predicted to propel the development of the pneumonia therapeutics market. Pneumonia is a lung disease that inflames the air sacs, commonly causing symptoms such as coughing, fever, and shortness of breath. A rise in pneumonia incidents can be credited to factors like increasing elderly population, air pollution, smoking, compromised immune systems, antibiotic resistance, and the spread of respiratory diseases such as COVID-19 or influenza. Pneumonia therapeutics play an instrumental role in combating the infection by targeting its root cause, be it bacteria, viruses, or fungi, through specified medications, providing support for recovery through oxygen therapy, anti-inflammatory drugs, and symptom control. For example, in January 2023, according to data from the National Center for Biotechnology Information, a US-based government agency, pneumonia impacts around 120 million people globally per year, causing an estimated 1.3 million deaths. Almost 80% of pediatric pneumonia deaths are seen in children below 2 years in underdeveloped countries. Thus, the rising incidence of pneumonia is catalyzing the expansion of the pneumonia therapeutics market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21258&type=smp
What Are the Leading Segments in the Global Pneumonia Therapeutics Industry?
The pneumonia therapeutics market covered in this report is segmented –
1) By Product: Drugs, Vaccine, Oxygen Therapy
2) By Infection: Hospital-Acquired Pneumonia (HAP), Community-Acquired Pneumonia (CAP), Ventilator-Associated Pneumonia (VAP)
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By End Use: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Drugs: Antibiotics, Antiviral Drugs, Antifungal Drugs, Corticosteroids, Other Drugs
2) By Vaccine: Pneumococcal Vaccines, Haemophilus Influenzae Type B (Hib) Vaccines, Influenza Vaccines, Other Vaccines
3) By Oxygen Therapy: High-Flow Nasal Cannula (HFNC), Non-Invasive Ventilation (NIV), Mechanical Ventilation, Other Oxygen Therapies
What Are the Key Market Trends in the Pneumonia Therapeutics Industry?
In the pneumonia therapeutics market, prominent firms are emphasizing the creation of innovative medication formulations and treatment strategies, such as antibiotic drugs, to combat antibiotic resistance and enhance patient outcomes. Antibiotic drugs are medications created specifically for the treatment of bacterial infections. For example, in June 2024, Orchid Pharma Limited, a pharmaceutical company from India, worked together with Cipla Limited, another Indian pharmaceutical firm, to launch cefepime-enmetazobactam. This combination antibiotic is employed to manage complicated infections such as UTIs and pneumonia, especially those that are resistant to other drugs. It contributes to the fight against bacterial resistance by ensuring effective treatment and reducing the need for more potent antibiotics.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/pneumonia-therapeutics-global-market-report
What Is the Regional Outlook for the Pneumonia Therapeutics Market?
North America was the largest region in the pneumonia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumonia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21258
This Report Delivers Insight On:
1. How big is the pneumonia therapeutics market, and how is it changing globally?
2. Who are the major companies in the pneumonia therapeutics market, and how are they performing?
3. What are the key opportunities and risks in the pneumonia therapeutics market right now?
4. Which products or customer segments are growing the most in the pneumonia therapeutics market?
5. What factors are helping or slowing down the growth of the pneumonia therapeutics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model